Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 96,254 shares, an increase of 257.5% from the June 15th total of 26,924 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily volume of 110,311 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Dogwood Therapeutics Price Performance

DWTX traded up $0.05 during trading on Tuesday, reaching $1.43. The company had a trading volume of 14,607 shares, compared to its average volume of 81,632. The company has a market cap of $48.09 million, a P/E ratio of -0.13 and a beta of 1.70. Dogwood Therapeutics has a 12 month low of $1.28 and a 12 month high of $9.50. The business’s fifty day moving average price is $1.61 and its 200 day moving average price is $2.34.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. As a group, sell-side analysts predict that Dogwood Therapeutics will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on DWTX. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. Weiss Ratings cut Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.